[Be cautious to treat choroidal neovascularization with anti-angiogenesis pharmacotherapy].
Choroidal neovascularization (CNV) especially CNV secondary to age related macular degeneration is becoming an increasing socio-medical problem as the global population aging. Recently, with novel insights in the pathogenesis of the disease, anti-angiogenesis pharmacotherapy ablated its way into ophthalmological practice and significantly changed the management of CNV, since at the first time achieving improvement in visual function. However, facing such promising drugs, we still need to take caution with the safety, long-time efficacy; to investigate more reasonable dosing schedule; to study the combined treatment strategies and so on,finally to find out the best individual clinical care for our patients.